预测结核病药物组合的早期杀菌活性,使用翻译性药理动力学-药理动力学建模方法
bioRxiv : the preprint server for biology
|February 12, 2026
概括
一个新的翻译性药理动力学-药理动力学 (PK-PD) 建模平台准确地预测了两种结核病 (TB) 药物组合的早期杀菌活性 (EBA),有助于更快的治疗方案开发.
科学领域:
- 药理学 药理学是指药理学的学科.
- 微生物学 微生物学
- 数学建模的数学建模
背景情况:
- 肺结核 (TB) 试验经常评估单一治疗的早期杀菌活性 (EBA),但最佳剂量可能无法转化为药物组合.
- 翻译性药理动力学-药理动力学 (PK-PD) 建模显示出从临床前数据预测人类反应的潜力,但其在组合中的使用是有限的.
研究的目的:
- 扩展和验证一个转化单一疗法PK-PD建模平台,用于预测两种药物结核病组合的EBA.
- 通过PK-PD建模,评估贝达奎林,普雷托曼尼德,线索利德和皮拉津胺之间的药物相互作用.
主要方法:
- 使用实证SUPER方法和机械的通用药理学相互作用模型来描述药物相互作用.
- 将两种相互作用模型与翻译PK-PD平台联系起来,并使用小鼠数据和IIa期临床结果 (NC-001研究) 进行验证.
主要成果:
- 确定了一致的相互作用模式,包括贝达奎林与普雷托曼尼德或线索利德之间的对抗性.
- 皮拉津胺是贝达奎林和普雷托曼尼德最有效的伴侣药物.
- 该平台合理地预测了各种两种药物组合的14天临床唾液殖民地形成单位数量,大多数观察都在95%的预测间隔内.
结论:
- 经过验证的翻译PK-PD平台可靠地预测了抗结核病药物组合的短期和长期结果.
- 该平台通过告知剂量选择和识别有效的伴随药物来支持加速治疗方案的开发.
更多相关视频
07:02A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development
Published on: February 11, 2019
10.3K
13:34A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
Published on: April 6, 2016
10.7K
相关概念视频
01:14Pharmacokinetic–Pharmacodynamic Relationship: Model Components
1
Pharmacokinetic-pharmacodynamic (PK–PD) modeling is essential in drug development and clinical pharmacology. It provides a quantitative framework to predict drug behavior and response over time. This approach integrates pharmacokinetics (PK), which describes the drug's absorption, distribution, metabolism, and excretion, with pharmacodynamics (PD), which characterizes the drug’s biological effects and mechanisms of action.The disposition kinetics of a drug determine its plasma...
1
01:24Pharmacokinetic–Pharmacodynamic Relationship: Problems
1
The empirical approach to drug therapy optimization relies on correlating pharmacological response with administered dosage. Such an approach can be costly, time-consuming, and often yields poor correlation due to variables like formulation factors and drug elimination characteristics. A more precise approach correlates response with plasma drug concentration or the amount of drug in the body, rather than dosage. This is achieved through pharmacokinetic-pharmacodynamic (PK/PD) modeling, which...
1
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
1
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
1
01:09Pharmacodynamic Models: Additive and Proportional Drug Effect Model
1
Drug response models describe how pharmacological agents interact with biological systems to produce measurable effects. Baseline responses are inherent physiological activities without a drug significantly influencing the observed pharmacological outcomes. Depending on the drug response model employed, these baseline responses may combine with the drug's effect in either an additive or proportional manner.Additive Drug Response ModelIn the additive model, the drug effect is independent of the...
1
01:18Pharmacodynamic Models: Emax Drug–Concentration Effect Model
6
The Emax drug-concentration effect model is central to pharmacodynamics in drug discovery and development. This model is predicated on the receptor occupancy theory, which posits that the effect of a drug is directly related to the number of receptors occupied by the drug and the resultant complex formation.The model describes the reversible interaction between a drug (C) and a receptor (R) to form a drug-receptor complex (RC). The kinetics of this interaction are quantified by an equation that...
6
01:28Pharmacokinetic–Pharmacodynamic Relationship: Dose to Pharmacological Effect
1
A drug’s dosage and pharmacokinetic properties determine how quickly it acts, how intense its effects are, and how long it lasts. Higher doses increase drug concentration at receptor sites, producing a hyperbolic curve when pharmacologic response is plotted against drug dose. Converting this scale to a log-linear format results in a sigmoidal curve, better representing dose–response relationships.For drugs following a one-compartment model, the pharmacologic response is directly...
1